The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Coronavirus
Disease modifying treatment
Myelin oligodendrocyte glycoprotein antibody-associated disorders
Neuromyelitis optica spectrum disorders
SARS-CoV-2
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
12
08
2021
revised:
30
10
2021
accepted:
10
11
2021
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
3
3
2022
Statut:
ppublish
Résumé
COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known. The aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed. The study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found. In NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known.
OBJECTIVE/METHODS
OBJECTIVE
The aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed.
RESULTS
RESULTS
The study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found.
CONCLUSION
CONCLUSIONS
In NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection.
Identifiants
pubmed: 35216782
pii: S2211-0348(21)00666-0
doi: 10.1016/j.msard.2021.103399
pmc: PMC8655726
pii:
doi:
Substances chimiques
Aquaporin 4
0
Autoantibodies
0
Myelin-Oligodendrocyte Glycoprotein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103399Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Mult Scler Relat Disord. 2021 Jun;51:102886
pubmed: 33744758
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Mult Scler Relat Disord. 2020 Sep;44:102245
pubmed: 32512287
Neurol Neuroimmunol Neuroinflamm. 2020 Jul 9;7(5):
pubmed: 32646885
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Muscle Nerve. 2020 Aug;62(2):254-258
pubmed: 32392389
J Neurol. 2021 Apr;268(4):1188-1190
pubmed: 32920657
Mult Scler. 2020 Sep;26(10):1256-1260
pubmed: 32662742
Eur Neurol. 2021;84(5):307-324
pubmed: 34044408
Neurology. 2021 Nov 9;97(19):e1870-e1885
pubmed: 34610987
Front Neurol. 2020 Sep 11;11:1053
pubmed: 33013676
Ann Rheum Dis. 2021 Sep;80(9):1137-1146
pubmed: 34049860
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Front Neurol. 2021 Mar 22;12:657037
pubmed: 33828524
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 4;7(5):
pubmed: 32503092
Mult Scler Relat Disord. 2021 Jul;52:102968
pubmed: 33940495
Mult Scler Relat Disord. 2020 Nov;46:102474
pubmed: 32892062
J Neurol. 2021 Dec;268(12):4479-4482
pubmed: 33904965
Eur J Neurol. 2021 Oct;28(10):3384-3395
pubmed: 33340215
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Mult Scler Relat Disord. 2020 Sep;44:102199
pubmed: 32554285
Eur J Neurol. 2021 Oct;28(10):3461-3466
pubmed: 33103295
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Neurol Neuroimmunol Neuroinflamm. 2021 Aug 24;8(5):
pubmed: 34429342
Neurol Neuroimmunol Neuroinflamm. 2021 Aug 26;8(6):
pubmed: 34446434